Press release
Tardive Dyskinesia Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | Key Companies - Addex Therapeutics, Contera Pharma, Teva Pharmaceutical, SOM Biotech, Mitsubishi Tanabe Pharma
DelveInsight's "Tardive Dyskinesia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Tardive Dyskinesia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The market report covers emerging drugs, treatment practices, market share of individual Tardive Dyskinesia therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Tardive Dyskinesia treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Tardive Dyskinesia: An Overview
According to the National Organization for Rare Disorders (NORD), Tardive dyskinesia (TD) is an involuntary neurological movement disorder caused by the use of dopamine receptor-blocking drugs that are prescribed to treat certain psychiatric or gastrointestinal conditions. Long-term use of these drugs may produce biochemical abnormalities in the area of the brain known as the striatum. The reason that some people who take these drugs may get tardive dyskinesia, and some people do not, is unknown. Tardive dystonia is a more severe form of tardive dyskinesia in which slower twisting movements of the neck and trunk muscles are prominent.
Tardive Dyskinesia is characterized by involuntary and abnormal movements of the jaw, lips, and tongue. Typical symptoms include facial grimacing, sticking out the tongue, sucking, or fish-like movements of the mouth. In some cases, patients also have irregular movement of the trunk and limbs. These movements are typically choreiform or choreoathetoid in type; although, athetosis of the extremities and axial and limb dystonia is often listed as part of the syndrome, as are gait and trunk posture abnormalities, such as rocking or rotary pelvic movements.
Tardive Dyskinesia Market Key Facts
• As per a study conducted by Cornett et al. (2017) titled "Medication-Induced Tardive Dyskinesia: A Review and Update", the occurrence of Tardive Dyskinesiais estimated to be 2-5% annually, and the condition occurs in 15-30% of those who receive long-term treatment with antipsychotic drugs [APDs]. In fact, Tardive Dyskinesia occurs in 20-50% of patients taking APDs. However, Tardive Dyskinesia is also associated with a wide variety of other medications.
• According to the Mental Health America (MIIA), Tardive Dyskinesia is estimated to affect at least 500,000 people in the US. Those who have been treated for schizophrenia, schizoaffective disorder, and/or bipolar disorder are particularly at risk. The older a person is, the more likely they are to develop persistent and irreversible tardive dyskinesia.
• As per the article published by Robert et al. (2019) titled "Tardive Dyskinesia Facts and Figures," TD affects an estimated 500,000 persons in the United States. About 60% to 70% of cases are mild, and about 3% are extremely severe. The prevalence rate is 20% to 30%. The annual incidence in patients older than 45 years is 15% to 30% after 1 year of treatment; the prevalence rate is about 50% to 60%.
Discover How Tardive Dyskinesia Market Will Grow by 2032:
https://www.delveinsight.com/report-store/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Tardive Dyskinesia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Tardive Dyskinesia therapies in the market. It also provides a detailed assessment of the Tardive Dyskinesia market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the market trend for each marketed Tardive Dyskinesia drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Tardive Dyskinesia Epidemiology
The epidemiology section covers detailed insights into the historical, and current Tardive Dyskinesia patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.
The Report Covers the Tardive Dyskinesia Epidemiology Segmented as -
• Total Prevalent Cases of Tardive Dyskinesia in the 7MM (2019-2032)
• Diagnosed Prevalent Cases of Tardive Dyskinesia in the 7MM (2019-2032)
• Severity-specific Diagnosed Prevalent Cases of Tardive Dyskinesia in the 7MM (2019-2032)
• Treatable Cases of Tardive Dyskinesia in the 7MM (2019-2032)
Get Key Insights Into the Evolving Tardive Dyskinesia Epidemiology Trends @
https://www.delveinsight.com/report-store/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Tardive Dyskinesia Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tardive Dyskinesia market or expected to be launched during the study period. The analysis covers the market share by Tardive Dyskinesia drugs, patient uptake by therapies, and sales of each drug.
The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.
The report also covers the Tardive Dyskinesia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Tardive Dyskinesia Therapeutics Assessment
Treatment of Tardive Dyskinesia is highly individualized. Since, Tardive Dyskinesiais caused by dopamine blockage, initial treatment includes gradual removal of the dopamine-blocking agents. Many times, these agents cannot be removed, as these agents are used for a variety of illnesses (such as gastrointestinal and psychiatric). The doctor may switch the patient to a different antipsychotic that may lessen Tardive Dyskinesia. Many available treatments for Tardive Dyskinesia offer some benefit to patients, but the response to treatment depends on the patient.
Several major pharma and biotech companies are developing therapies for Tardive dyskinesia. Currently, Mitsubishi Tanabe Pharma is leading the therapeutics market with its Tardive dyskinesia drug candidates in the most advanced stage of clinical development.
Leading Companies in the Tardive Dyskinesia Therapeutics Market Include
• Addex Therapeutics
• Contera Pharma
• Teva Pharmaceutical
• SOM Biotech
• Mitsubishi Tanabe Pharma
And Many Others
Emerging and Marketed Tardive Dyskinesia Therapies Covered in the Report Include
• SOM3366: SOM Biotech
Som Biotech's SOM3366 is an oral VMAT2 inhibitor (vesicular monoamine transporter 2) for the symptomatic treatment of Tardive Dyskinesia. The drug is currently finishing preclinical development in Tardive Dyskinesia.
• Zydis ODT : Cycle Pharmaceuticals
Cycle Pharmaceuticals, in collaboration with Catalent is developing a low dose treatment for tardive dyskinesia. The Zydis ODT (orally dissolving tablet), developed by them is to improve the compliance of patients who have difficulty in swallowing tablets, such as children, the elderly and bedridden patients.
Learn More About the Emerging Therapies & Key Companies in the Tardive Dyskinesia Therapeutics Market:
https://www.delveinsight.com/sample-request/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Tardive Dyskinesia Competitive Intelligence Analysis
4. Tardive Dyskinesia Market Overview at a Glance
5. Tardive Dyskinesia Background and Overview
6. Tardive Dyskinesia Patient Journey
7. Tardive Dyskinesia Epidemiology and Patient Population
8. Tardive Dyskinesia Treatment Algorithm, Current Treatment, and Medical Practices
9. Tardive Dyskinesia Unmet Needs
10. Key Endpoints of Tardive Dyskinesia Treatment
11. Tardive Dyskinesia Marketed Products
12. Tardive Dyskinesia Emerging Therapies
13. Tardive Dyskinesia Seven Major Market Analysis
14. Attribute Analysis
15. Tardive Dyskinesia Market Outlook (7 major markets)
16. Tardive Dyskinesia Access and Reimbursement Overview
17. KOL Views on the Tardive Dyskinesia Market.
18. Tardive Dyskinesia Market Drivers
19. Tardive Dyskinesia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Emphysema Market
https://www.delveinsight.com/report-store/emphysema-market
Hairy Cell Leukemia (HCL) Market
https://www.delveinsight.com/report-store/hairy-cell-leukemia-hcl-market
Cancer Cachexia (CC) Market
https://www.delveinsight.com/report-store/cancer-cachexia-cc-market-insights
Diabetes Market
https://www.delveinsight.com/report-store/diabetes-market
Panuveitis Market
https://www.delveinsight.com/report-store/panuveitis-market
Global Kinase Inhibitor in Autoimmune Diseases Market
https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market
mRNA Vaccine and Therapeutics Market
https://www.delveinsight.com/report-store/mrna-vaccine-and-therapeutics-market
Negative Pressure Wound Therapy Systems Market
https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market
Hematuria Market
https://www.delveinsight.com/report-store/hematuria-market
Smart Inhalers Market
https://www.delveinsight.com/report-store/smart-inhalers-market
Audiology Devices Market
https://www.delveinsight.com/report-store/audiology-devices-market
Deep Brain Stimulation Devices Market
https://www.delveinsight.com/report-store/deep-brain-stimulation-devices-market
Prosthetic Heart Valve Market
https://www.delveinsight.com/report-store/prosthetic-heart-valve-market
Tongue Cancer Market
https://www.delveinsight.com/report-store/tongue-cancer-market
Cancer Vaccines Market
https://www.delveinsight.com/report-store/cancer-vaccines-market
CAR-T Pipeline Insight
https://www.delveinsight.com/report-store/car-t-pipeline-insight
Concussions Market
https://www.delveinsight.com/report-store/concussions-market
Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Physiotherapy Equipment Market
https://www.delveinsight.com/report-store/physiotherapy-equipment-market
Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market
Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market
Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market
Seborrhoeic Dermatitis Market
https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market
Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market
Migraine Market
https://www.delveinsight.com/report-store/migraine-market
Pegfilgrastim Biosimilar
https://www.delveinsight.com/report-store/pegfilgrastim-biosimilar-insight
Renal Vasculitis Market
https://www.delveinsight.com/report-store/renal-vasculitis-market
Dense Deposit Disease Market
https://www.delveinsight.com/report-store/dense-deposit-disease-market
Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market
Lipodystrophy Market
https://www.delveinsight.com/report-store/lipodystrophy-market
Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
Anaplastic Astrocytoma Market
https://www.delveinsight.com/report-store/anaplastic-astrocytoma-market
Singapore Healthcare Outlook
https://www.delveinsight.com/report-store/singapore-healthcare-outlook-report
Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tardive Dyskinesia Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | Key Companies - Addex Therapeutics, Contera Pharma, Teva Pharmaceutical, SOM Biotech, Mitsubishi Tanabe Pharma here
News-ID: 3155105 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Tardive
Tardive Dyskinesia Treatment Market Analysis By Drug Class & Distribution Channe …
The Tardive Dyskinesia Treatment Market is expected to Reach a CAGR of 4% during the forecast period (2024-2031).
Tardive Dyskinesia Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it…
Tardive Dyskinesia Market Report and Forecast 2024-2032
The tardive dyskinesia market size is anticipated to grow at a CAGR of 3.2 % during the forecast period of 2024-2032, driven by growing awareness about the importance of monitoring patients on long-term antipsychotic therapy for early signs of tardive dyskinesia in the major markets.
Tardive Dyskinesia: Introduction
Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive body movements. It primarily affects the face, causing grimacing, blinking, or lip-smacking, but can…
Global Tardive Dyskinesia (TD) Treatment Market - Opportunities & Forecasts, 202 …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global tardive dyskinesia (td) treatment market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able to…
Tardive Dyskinesia Drugs Market Competitor Landscape, Opportunity Analysis, Grow …
Tardive neurological disorder (TD) may be a kind of dyskinesia that's tough to treat. it's a nerve disorder characterised by involuntary movements like jaw, lips, and tongue, thought-about as grimacing, protrusive the tongue out, and lip smack. another symptoms square measure a private experiencing involuntary movement of the lower and higher extremities and additionally respiratory choking.
Get HOLISTIC Request Sample Copy:https://www.coherentmarketinsights.com/insight/request-sample/218
consistent with Center for Drug analysis and analysis, dyskinesia will…
Tardive Dyskinesia (TD) Treatment Drugs Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Tardive Dyskinesia (TD) Treatment Drugs Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Tardive Dyskinesia (TD) Treatment Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$…
Antioxidants May Aid in the Treatment of Tardive Dyskinesia
Memphis, TN (May 9, 2019) – Today, The Primary Care Companion for CNS Disorders published a case report on the use of antioxidants in the treatment of tardive dyskinesia. While new pharmacologic discoveries have occurred in the area of movement disorders, their use comes with a large price tag. Thus, for mild cases, clinicians may want to seek out more cost-effective options. Antioxidants may serve a role in the prevention…
